Quince Therapeutics (QNCX) Operating Leases (2019 - 2026)

Quince Therapeutics has reported Operating Leases for 8 years, with the latest figure at $293000.0 in Q1 2026.

• On a quarterly basis, Operating Leases fell 39.59% year-over-year to $293000.0 in Q1 2026; TTM through Mar 2026 was $293000.0, a 39.59% decrease from a year earlier, with the FY2025 full-year figure at $330000.0, down 16.24% from the prior year.
• Operating Leases was $293000.0 for Q1 2026 at Quince Therapeutics, down from $330000.0 in the prior quarter.
• The five-year high for Operating Leases was $551000.0 in Q3 2024, with the low at $34000.0 in Q3 2022.
• Average Operating Leases over 5 years is $337692.3, with a median of $385000.0 recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Operating Leases sank 94.43% in 2022, then climbed 2.34% in 2024.
• Over 5 years, Operating Leases stood at $34000.0 in 2022, then surged by 1032.35% to $385000.0 in 2023, then advanced by 2.34% to $394000.0 in 2024, then decreased by 16.24% to $330000.0 in 2025, then declined by 11.21% to $293000.0 in 2026.
• The last three Operating Leases figures came in at $293000.0 (Q1 2026), $330000.0 (Q4 2025), and $359000.0 (Q3 2025), per Business Quant data.